Search | IOVS | ARVO Journals

Showing 1 – 20 of 89

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1157. doi:

ARVO Annual Meeting Abstract June 2020

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Grace Tsai; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1909. doi:

ARVO Annual Meeting Abstract June 2020

Classification of disease severity in Retinitis Pigmentosa

Bushra Usmani; Mustafa Iftikhar; Marili Lemus; Peter A Campochiaro; Jose Alain Sahel; Hendrik P Scholl; Syed Mahmood Ali Shah

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3024. doi:

ARVO Annual Meeting Abstract June 2020

Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors

Kun Ding; Jikui Shen; Sean Hackett; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4490. doi:

ARVO Annual Meeting Abstract July 2019

Suprachoroidal AAV8-Vectored Gene Transfer Provides Widespread Transgene Expression in RPE and Retina

Kun Ding; Jikui Shen; Zibran Hafiz; Sean Hackett; Raquel Formica; Valeria E Lorenc; Rishi Chadha; Minie Zhang; Sherri Van Everen; Nicholas Buss; Michele Fiscella; Olivier Danos; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2923. doi:

ARVO Annual Meeting Abstract July 2019

Co-operative Activities of VEGF and SDF-1 in Retina

DA LONG; Jikui Shen; Sean Hackett; Lili Lu; Zibran Hafiz; Qiang Gong; Peter A Campochiaro; Jingwen Yu; Jinpeng Wang; Scott Ferguson; Wen-Chuan Chou; Qin Yang; Hui Kang

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3262. doi:

ARVO Annual Meeting Abstract July 2019

A bispecific aptamer targeting both VEGF and Angiopoietin-2 for treating retinal diseases

Scott Ferguson; DA LONG; Qin Yang; Hui Kang; Jingwen Yu; Wen-Chuan Chou; Matthew Vukovich; Raquel Formica; Zibran Hafiz; Peter A Campochiaro; Jinpeng Wang; Qiang Gong

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3665. doi:

ARVO Annual Meeting Abstract July 2019

AXT107, a Peptide that Disrupts Integrins, Suppresses Vascular Leakage in the Setting of Ocular Inflammation

Raquel Formica; Sean Hackett; Zibran Hafiz; Adam Mirando; Jordan J Green; Aleksander S Popel; Niranjan B Pandey; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4073. doi:

Retina October 2018

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection

PDF

Yu Zhang; Hojjat Bazzazi; Raquel Lima e Silva; Niranjan B. Pandey; Jordan J. Green; Peter A. Campochiaro; Aleksander S. Popel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(12):5266-5276. doi: https://doi.org/10.1167/iovs.17-23632

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

Test-retest Reliability of MP1 and MAIA Microperimetry in Retinitis Pigmentosa

Mustafa Iftikhar; Jiangxia Wang; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):30. doi:

ARVO Annual Meeting Abstract July 2018

Progression of Retinitis Pigmentosa on Multimodal Imaging: The PREP-1 Study

Syed Mahmood Ali Shah; Mustafa Iftikhar; Bushra Usmani; Abanti Sanyal; Ramandeep Kaur; Marili Lemus; April Nefalar; Saleema A. Kherani; Simrat Sodhi; Saghar Bagheri; Etienne M Schonbach; Nadia Junaid; Peter A Campochiaro; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):45. doi:

ARVO Annual Meeting Abstract July 2018

Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents

Saleema A. Kherani; Roomasa Channa; Rimsha Shaukat; Olukemi Adeyemo; Mustafa Iftikhar; Adrienne Scott; Akrit Sodhi; James T Handa; Ingrid Zimmer-Galler; Adam Wenick; Sharon D Solomon; Mira Sachdeva; Catherine B Meyerle; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):825. doi:

ARVO Annual Meeting Abstract July 2018

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Hugo Quiroz-Mercado; David S Boyer; Peter A Campochiaro; Jeffrey S. Heier; Peter K Kaiser; Julie Kornfield; Baruch D Kuppermann; Vicken H Karageozian; Hampar L Karageozian; Lisa Karageozian; John Y Park; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1960. doi:

ARVO Annual Meeting Abstract July 2018

A small biomimetic collagen IV derived peptide reduces leakage and suppresses ocular neovascularization in mouse models

Raquel Formica; Valeria E Lorenc; Niranjan B Pandey; Ji-kui Shen; Jayoung Kim; Aleksander S Popel; Jordan Green; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3269. doi:

ARVO Annual Meeting Abstract July 2018

Hepatocyte growth factor (HGF) induces vascular leakage in the retina

Valeria E Lorenc; Raquel Formica; Seth Fortmann; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5308. doi:

ARVO Annual Meeting Abstract July 2018

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

Mitchell G Brigell; Victor H Gonzalez; Darren J Bell; Arshad M. Khanani; Barbara Withers; Laura Gambino; Peter A Campochiaro; Kevin G Peters; Steve Pakola

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1252. doi:

ARVO Annual Meeting Abstract July 2018

A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal Vascular Leakage

Kevin G Peters; Ji-kui Shen; Yuanyuan liu; Astrid Nottebaum; Dietmar Vestweber; Michael Flynn; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):199. doi:

ARVO Annual Meeting Abstract June 2017

A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD)

Michael Byrne; Natalie Gagne; Gulnar Hafiz; Tahreem Mir; Manasa Survi; Laurie Barefoot; James Cardia; Karen Bulock; Pamela A Pavco; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3210. doi:

ARVO Annual Meeting Abstract June 2017

Hepatocyte growth factor (HGF) stimulates ocular neovascularization and vascular leakage and may contribute to NV and macular edema in ischemic retinopathies.

Valeria E Lorenc; Raquel Formica; Seth Daniel Fortmann; Yogita Kanan; Sean Hackett; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4065. doi:

ARVO Annual Meeting Abstract June 2017

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

Peter A Campochiaro; Raafay Sophie; Ann Clark; Na Lu; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4626. doi:

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Classification of disease severity in Retinitis Pigmentosa

Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors

Suprachoroidal AAV8-Vectored Gene Transfer Provides Widespread Transgene Expression in RPE and Retina

Co-operative Activities of VEGF and SDF-1 in Retina

A bispecific aptamer targeting both VEGF and Angiopoietin-2 for treating retinal diseases

AXT107, a Peptide that Disrupts Integrins, Suppresses Vascular Leakage in the Setting of Ocular Inflammation

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection

Test-retest Reliability of MP1 and MAIA Microperimetry in Retinitis Pigmentosa

Progression of Retinitis Pigmentosa on Multimodal Imaging: The PREP-1 Study

Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

A small biomimetic collagen IV derived peptide reduces leakage and suppresses ocular neovascularization in mouse models

Hepatocyte growth factor (HGF) induces vascular leakage in the retina

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal Vascular Leakage

A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD)

Hepatocyte growth factor (HGF) stimulates ocular neovascularization and vascular leakage and may contribute to NV and macular edema in ischemic retinopathies.

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

To View More...

You must be signed into an individual account to use this feature.